Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has been awarded a grant for $2.2 million from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), aimed at advancing the development of novel influenza therapeutics for the treatment of seasonal and pandemic influenza.

2 Nov 2009

Pulmatrix raises $30.2 million through Series B financing

Pulmatrix, a clinical stage biotechnology company discovering and developing a new class of therapies for the treatment and prevention of infectious and progressive respiratory diseases, today announced that it has secured $30.2 million in Series B financing. ARCH Venture Partners and Novartis Bioventures Fund co-led the round with participation from existing investors Polaris Venture Partners and 5AM Ventures.

2 Nov 2009

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

More than 80 percent of hepatitis C patients in each arm of the Phase 2 Study C208 achieved a sustained viral response (SVR) with a telaprevir-based regimen according to results of an intent-to-treat (ITT) analysis announced today by Vertex Pharmaceuticals Incorporated.

2 Nov 2009

Bacteria use a well-studied communication system to resist antibiotics

Researchers from the University of Copenhagen and the Technical University of Denmark along with other collaborators in Denmark and the US found that the bacterium Pseudomonas aeruginosa can 'switch on' production of molecules that kill white blood cells - preventing the bacteria being eliminated by the body's immune system.

1 Nov 2009

University of Iowa receives a $26.4M gift commitment from the Pappajohns

University of Iowa President Sally Mason announced today a $26.4 million gift commitment from longtime UI benefactors John and Mary Pappajohn of Des Moines -- the largest single gift commitment ever for the UI from individual Iowa donors -- and said it will provide the university's new interdisciplinary Institute for Biomedical Discovery with "the catalyst it needs to reach its full potential."

30 Oct 2009

Roger Tung to receive 2009 Mass High Tech All Star award for his contributions to pharmaceutical industry

Concert Pharmaceuticals, Inc. announced today that Roger Tung, Ph.D., President and Chief Executive Officer, has been named a 2009 Mass High Tech All Star for his contributions to the pharmaceutical industry.

29 Oct 2009

GeneGo to launch new web site with high quality pathway content

GeneGo, Inc., the leading systems biology tools company, announced today that they will be launching a new web site with FREE high quality pathway content. On www.genego.com, anyone can now search for genes, proteins, compounds, processes and diseases and access high quality manually curated pathway maps for human, mouse and rat signaling and metabolism.

29 Oct 2009

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

DiscoveryBioMed, Inc. (DBM) today announced that it has been awarded a Phase 1 Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The $308,000 grant will be used to advance certain small molecule drug discovery programs designed to correct the genetic mutation most common to cystic fibrosis (CF).

28 Oct 2009

MMRF raises over $1.8 million at its 13th annual Fall Gala

The Multiple Myeloma Research Foundation (MMRF) raised over $1.8 million at its 13th annual Fall Gala held on Saturday evening in Greenwich, Conn. Funds raised at this premier fundraising event, attended by more than 1,000 guests, will support the MMRF’s efforts to accelerate the development of the next generation of treatments for patients with multiple myeloma, a rare and incurable blood cancer, and to find a cure for the disease.

28 Oct 2009

ACC's initiative for health care reform

As lawmakers debate health care reform, business innovator Lou Weisbach and Clinton White House health care advisor Dr. Richard Boxer are available for interviews to discuss a glaring, missing element of the forthcoming health care legislation: reducing health care costs -- and saving lives -- by preventing and curing disease.

27 Oct 2009

Protein crucial for insulin regulation may play a role in diabetes

A cellular protein from a family involved in several human diseases is crucial for the proper production and release of insulin, new research has found, suggesting that the protein might play a role in diabetes.

27 Oct 2009

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution

Gilead Sciences, Inc. today announced that aztreonam for inhalation solution, an investigational product for the treatment of infections due to Pseudomonas aeruginosa (P. aeruginosa) in patients with cystic fibrosis (CF), is scheduled to be reviewed by the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration (FDA) on December 10, 2009.

27 Oct 2009

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Solvay Pharmaceuticals, Inc. announced that new data demonstrate that CREON®( )(pancrelipase) Delayed-Release Capsules significantly improves a key measure of fat absorption in adults with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery.

27 Oct 2009

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

PTC Therapeutics, Inc. (PTC) today announced it is expanding the development of ataluren, an investigational new drug, to a third indication with the initiation of a Phase 2a clinical trial in nonsense mutation hemophilia A (nmHA) and hemophilia B (nmHB).

26 Oct 2009

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

Napo Pharmaceuticals, Inc. has in-licensed from the University of California Regents additional small-molecule cystic fibrosis transmembrane conductance regulator (CFTR) inhibitor technology including gastrointestinal (GI) and polycystic kidney disease (PKD) indications.

26 Oct 2009

American Thoracic Society releases new clinical guidelines for pulmonary exacerbation of cystic fibrosis

The American Thoracic Society has released new clinical guidelines for the treatment of exacerbations in cystic fibrosis based on a review of the literature on current clinical practices.

23 Oct 2009

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Hydra Biosciences today announced that they have entered into an agreement with Cubist Pharmaceuticals, Inc. for a joint collaboration to develop novel ion channel drugs.

20 Oct 2009

Positive results from Transave's Phase II ARIKACE clinical trials

Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.

20 Oct 2009

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

Alnara Pharmaceuticals, a pharmaceutical company developing novel, non-systemic orally delivered protein therapeutics for the treatment of metabolic diseases, today announced results from an international, Phase 3 open-label, long-term safety study demonstrating the safety and nutritional benefits of liprotamase, a novel pancreatic enzyme replacement therapy (PERT) for patients with cystic fibrosis (CF).

19 Oct 2009

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

NanoBio Corporation today announced compelling preclinical data for NB-401, a nebulized nanoemulsion-based agent that kills highly drug-resistant strains of bacteria commonly found in cystic fibrosis patients. Currently there are limited treatment options available that effectively address these resistant bacteria. The study results are being presented today at the 2009 Annual North American Cystic Fibrosis Conference (NACFC) in Minneapolis, Minn.

19 Oct 2009

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

NIAID awards Pulmatrix $2.2M grant for developing novel influenza therapeutics

Pulmatrix raises $30.2 million through Series B financing

Vertex Pharmaceuticals announces study results of telaprevir-based regimen

Bacteria use a well-studied communication system to resist antibiotics

University of Iowa receives a $26.4M gift commitment from the Pappajohns

Roger Tung to receive 2009 Mass High Tech All Star award for his contributions to pharmaceutical industry

GeneGo to launch new web site with high quality pathway content

NIH awards DiscoveryBioMed grant to develop therapies for cystic fibrosis

MMRF raises over $1.8 million at its 13th annual Fall Gala

ACC's initiative for health care reform

Protein crucial for insulin regulation may play a role in diabetes

Anti-Infective Drugs Advisory Committee to review aztreonam for inhalation solution

New data demonstrates CREON Delayed-Release Capsules improve fat absorption in adults with EPI

Phase 2a clinical trial in nonsense mutation hemophilia A and hemophilia B initiated

Additional CFTR inhibitor technology licensed to Napo Pharmaceuticals

American Thoracic Society releases new clinical guidelines for pulmonary exacerbation of cystic fibrosis

Hydra Biosciences and Cubist Pharmaceuticals join to develop novel ion channel drugs

Positive results from Transave's Phase II ARIKACE clinical trials

Alnara Pharmaceuticals’ announces results of its international Phase 3 study of liprotamase

NanoBio's NB-401 preclinical data to be presented at the 2009 North American Cystic Fibrosis Conference

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Cystic Fibrosis News and Research

Latest Cystic Fibrosis News and Research

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Newsletters you may be interested in